Drug Discovery & DDS– category –
-
Exosome Delivery: 6-fold Paclitaxel concentration for GBM specs
Zuglueducation.com Unknown Overview Exosome-based drug delivery systems have achieved breakthrough results in a Phase I/II clinical trial for glioblastoma multiforme (GBM). Paclitaxel-loaded exosomes, derived from patient mesenchymal ste... -
NTS231: Nutshell Therapeutics’ AI-driven 24-month IND timeline
AllSci USA Overview Nutshell Therapeutics received U.S. FDA Investigational New Drug (IND) clearance for NTS231, a covalent allosteric molecular glue degrader of NRF2. Remarkably, this was achieved in just 24 months from target nominatio... -
ARO-DIMER-PA: Arrowhead’s Phase 1/2a siRNA knockdown specs
Cyagen Lab Notes USA Overview Arrowhead Pharmaceuticals announced promising interim Phase 1/2a clinical data for ARO-DIMER-PA, a novel dual-function RNAi therapeutic targeting cardiometabolic diseases. This single siRNA molecule simultan... -
Drug Discovery & DDS Weekly Report September 26, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report September 26, 2026 (PDF) — Download Weekly Report September 26, 2026 (PDF) — DownloadDownload 🎙 Podcast Septe... -
AlphaFold: 2,800+ AI viral protein structures explained
Mirage News International Overview AlphaFold has significantly expanded its database to include AI-predicted protein complex structures for over 2,800 viruses, prioritizing those known to infect humans, to enhance global pandemic prepare... -
UZEDY: Teva’s risperidone real-world data and cost specs
Teva (Press Release) Israel Overview Teva announced new real-world data at Psych Congress 2026, demonstrating that UZEDY® (risperidone extended-release injectable) for schizophrenia significantly improved treatment adherence and reduced ... -
Enicepatide: Roche’s Phase II results for diabetes and obesity
Roche Switzerland Overview On September 22, 2026, Roche announced positive topline Phase II results for its once-weekly dual GLP-1/GIP receptor agonist, enicepatide (CT-388), in adults with type 2 diabetes and overweight or obesity. The ... -
SORT LNPs explained: Novel 5th lipid component for organ delivery
Patsnap Singapore Overview Patsnap's September 18, 2026 analysis highlights Selective Organ Targeting (SORT) Lipid Nanoparticles (LNPs) as a groundbreaking technology for highly efficient, organ-specific delivery of nucleic acid payloads... -
FDA: Non-animal testing standard roadmap and 2030 timeline
Vertex AI Search USA Overview The FDA announced plans to remove animal testing references from drug regulations, clarifying that companies can seek drug approval without animal data. This pivotal shift encourages the use of alternative m... -
Sotyktu: Bristol Myers Squibb’s first oral TYK2 inhibitor FDA specs
MarketBeat USA Overview Bristol Myers Squibb (BMS) announced FDA approval on March 6, 2026, for Sotyktu® (deucravacitinib), an oral selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of active psoriatic arthritis in adults. ...
